Recombinant factor VIIa and thromboembolic events [6]

JAMA

Volumn 296, Issue 1, 2006, Pages 43-44

  Dutton, Richard P ^a   Stein, Deborah M ^a   Hess, John R ^a   Scalea, Thomas M ^a  

^a R ADAMS COWLEY SHOCK TRAUMA CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE SLOWING FACTOR; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 7; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ARTERY INJURY; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; CLINICAL TRIAL; DATA BASE; DOSE RESPONSE; DRUG USE; EXTRACORPOREAL CIRCULATION; FOOD AND DRUG ADMINISTRATION; HUMAN; INJURY; LETTER; LIVER CIRRHOSIS; MEDICAL PRACTICE; PRIORITY JOURNAL; PROPHYLAXIS; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; TRAUMATOLOGY; UNITED STATES; CHEMICALLY INDUCED DISORDER; NOTE; RISK;

ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; FACTOR VII; HUMANS; RECOMBINANT PROTEINS; RISK; THROMBOEMBOLISM;

EID: 33745593506     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.1.43-b     Document Type: Letter

References (4)

1. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293-298.
2. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma. 2004;57:709-719.
3. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8-18.
4. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-785.